Efficacy of extract of of Zingiber cinnamomum and zataria multiflora in covid-19 disease

Comparison Efficacy of extract plants of Zingiber , cinnamon , zataria multiflora with standard protocol in treatment and clinical improvement of patients with moderate to severe symptoms of covid-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20081011001323N25

Enrollment

Registered

2020-05-17

Start date

2020-05-21

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19. COVID-19

Interventions

Intervention 1: Intervention group: In this group, in addition to the standard daily intervention, a capsule of a combined extract of 3 plants of Zingiber cinnamon and zataria multiflora( 200 mg drie

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age over 18 years suffering from CAovid-19 with moderate to severe symptoms Having informed consent for entrance of study

Exclusion criteria

Exclusion criteria: Developing any complication during study Covid-19 patients with poor condition(very ill or intubated) Inability to use oral drugs Presence of any concomitant cardiac,hepatic or renal disease Having any allergy to chemical or herbal drugs Lack of desire to continue studying

Design outcomes

Primary

Measure	Time frame
Clinical symptoms ( presence and severity of dry cough). Timepoint: 0--3--7- 10-14 days after starting intervention. Method of measurement: Physical examination,questionnaire.;Temperature. Timepoint: 0--3--7- 10-14 days after starting intervention. Method of measurement: Thermometer.;Clinical symptoms (dyspnea). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 3,7 10 and 14 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Respiratory rate. Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 3,7 10 and 14 from the initiation, is recorded. Method of measurement: Counting the number of breaths per minute.;Blood pressure and pulse. Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 3,7 10 and 14 from the initiation, is recorded. Method of measurement: With sphygmomanometer and pulse control.;Oxygen saturation. Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 3,7 10 and 14 from the initiation, is recorded. Method of measurement: pulseoximeter.;Inflammatory response. Timepoint: Days 0,7. Method of measurement: Check of IL6,IL4,CBC,CRP,ESR.;Imaging findings. Timepoint: on the first and 7th day of treatment. Method of measurement: by chest x ray and CTscan.	—

Measure

Time frame

Clinical symptoms ( presence and severity of dry cough). Timepoint: 0--3--7- 10-14 days after starting intervention. Method of measurement: Physical examination,questionnaire.;Temperature. Timepoint: 0--3--7- 10-14 days after starting intervention. Method of measurement: Thermometer.;Clinical symptoms (dyspnea). Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 3,7 10 and 14 from the initiation, is recorded. Method of measurement: Physical examination,questionnaire.;Respiratory rate. Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 3,7 10 and 14 from the initiation, is recorded. Method of measurement: Counting the number of breaths per minute.;Blood pressure and pulse. Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 3,7 10 and 14 from the initiation, is recorded. Method of measurement: With sphygmomanometer and pulse control.;Oxygen saturation. Timepoint: Daily monitoring, but the result of baseline (before the initiation of intervention), and day 3,7 10 and 14 from the initiation, is recorded. Method of measurement: pulseoximeter.;Inflammatory response. Timepoint: Days 0,7. Method of measurement: Check of IL6,IL4,CBC,CRP,ESR.;Imaging findings. Timepoint: on the first and 7th day of treatment. Method of measurement: by chest x ray and CTscan.

—

Secondary

Measure	Time frame
Drug side effects. Timepoint: During treatment and one week later. Method of measurement: With observation, physical exam and report of patients.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSadrollah Mehrabi

Yasouj University of Medical Sciences

sadrollahm@yahoo.com+98 74 3322 1812

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026